Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium (SMC) has accepted dexamethasone intravitreal implant (Ozurdex®) for restricted use within NHS Scotland for the treatment of adult patients with macular oedema following either branch retinal vein occlusion or central retinal vein occlusion.
The SMC states that it is restricted for use in adults with macular oedema:
. following central retinal vein occlusion (CRVO) and
. in patients with branch retinal vein occlusion (BRVO) who are not clinically suitable for laser treatment including patients with (Read more...)